BioPattern extracts compound structures, applicants and competitive signals from Chinese pharmaceutical patents — the filings your current databases can't read — and delivers them as clean datasets, reports and an API.
Why global pharma misses half the competitive picture
Chinese patents are written in Mandarin. Most Western BD and CI teams rely on delayed, partial translations — or skip them entirely.
Existing databases are built for humans, cost $50K+ per year, and offer no API. Compound structures inside Chinese filings stay locked in images.
Competitive intelligence, license-in scouting and FTO analysis all have a China-shaped gap. That gap is where deals are lost.
A fully licensed, auditable pipeline
Sourced from EPO Open Patent Services under a full commercial license (OPS T&C §3.1 / §4.6). Extracted data only — no raw document redistribution. Structure recognition verified at 0 errors in a 60-sample human audit; 100% bibliographic coverage.
One of immunology's hottest targets — fully mapped across Chinese filings
| Rank | Applicant | Patents | Profile |
|---|---|---|---|
| 1 | Hoffmann-La Roche | 17 | Multinational pharma |
| 2 | Janssen Pharmaceutica (J&J) | 11 | Multinational pharma |
| 3 | Innate Tumor Immunity | 10 | US biotech |
| 4 | Ventus Therapeutics | 7 | US biotech |
| 5 | Hangzhou Matrix Bio | 5 | Chinese biotech |
Multi-heterocycle systems dominate the scaffold distribution (C07D 401/471), fused N-heterocycles form the largest single family, and natural-product derivatives are a distinct Chinese niche. Full analysis in the report.
Track Chinese filings in your target area weekly. Spot new entrants, new scaffolds and family expansions before they surface in Western sources.
Identify licensable compounds from Chinese universities and biotechs, with structures and applicants already normalized for triage.
Cover the Chinese flank of your FTO analysis. Avoid late-stage surprises from CN-only families invisible in English-language tools.
Stream deduplicated, validated structures into your models. Chinese patents add chemotypes absent from ChEMBL-class sources.
Start with a pilot. Scale when the data proves itself.
10-page analyst report: coverage statistics, top applicants, scaffold distribution, technology and engagement options. Free to download.
